Trial reportCNS neuroscience & therapeutics2026
Theta tACS Over the Medial Frontal Cortex Modulates Executive Function in Parkinson's Disease: A Randomized, Sham-Controlled Study.
Trial report in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240272 (Modulation of Executive Functions and Speech in Parkinson's Disease by Theta tACS Targeted at the Medial Frontal Cortex), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Modulation of Executive Functions and Speech in Parkinson's Disease by Theta tACS Targeted at the Medial Frontal Cortex
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundExecutive dysfunction is a common non-motor symptom of Parkinson's disease (PD) and has been linked to dysfunction of the medial frontal cortex (MFC). This randomized, sham-controlled study investigated whether high-definition transcranial alternating current stimulation (HD-tACS) over the MFC could improve executive function in PD.
methodsTwenty-eight PD patients were randomized to receive either active 6-Hz HD-tACS or sham stimulation over the MFC for 10 daily sessions. Executive function was assessed using the Digit Span Test (DST), Trail Making Test (TMT), Verbal Fluency Test (VFT), the Simon task, and the stop-signal task (SST). Functional near-infrared spectroscopy (fNIRS) was employed to assess prefrontal hemodynamic responses during a separate VFT task.
resultsRelative to sham stimulation, active 6-Hz HD-tACS induced significant improvements in TMT-A, TMT-B, and semantic VFT performance, along with reduced VFT-evoked oxyhemoglobin responses in the right dorsolateral prefrontal cortex. Baseline-adjusted post-intervention analyses revealed a smaller Simon effect and a higher inhibition rate in the active HD-tACS group. No significant stimulation-specific effects were observed for forward or backward DST, phonemic VFT, or SST reaction time.
conclusionThese findings provide neurobehavioral evidence that 6-Hz HD-tACS over the MFC may selectively improve executive function in PD, highlighting the potential of oscillatory neuromodulation for cognitive rehabilitation.
trial registrationThis trial was registered at ClinicalTrials.gov (No. NCT07240272) on November 20, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.